Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

▤ Summary

Verastem Oncology reported positive updated results from its RAMP 205 study in first-line metastatic pancreatic cancer. The company said the avutometinib and defactinib combination, given with standard chemotherapy, showed encouraging survival, response, and safety data in 29 patients. The release also points to continued development work, future strategic collaboration opportunities, and additional data coming from the ongoing trial. This is relevant to readers tracking biopharma pipeline progress and clinical-stage program momentum.

▦ Linked Companies